Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Richard Tomasini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0869-0811; OpenAlex author ID A5058115602. Sources: OpenAlex.

Their work

Papers
28 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
99
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 3 papers · 2022: 4 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 28

  1. Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer. Last author DOI 10.1172/jci197733↗
  2. Co-translational O-glycosylation driven by GALNTs spatial reprogramming fosters pancreatic cancer growth Co-author DOI 10.64898/2026.09.04.749345↗
  3. The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. Co-author DOI 10.1126/sciadv.adu2276↗
  4. High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer. Co-author DOI 10.1002/path.6212↗
  5. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer. Last author DOI 10.1186/s12964-023-01388-7↗
  6. SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-326610↗
  7. Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer. Co-author DOI 10.1038/s41467-022-29659-w↗
  8. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. Last author DOI 10.1126/scisignal.abg8191↗
  9. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. Co-author DOI 10.15252/embj.2021110466↗
  10. Cancer Associated Fibroblast (CAF) Regulation of PDAC Parenchymal (CPC) and CSC Phenotypes Is Modulated by ECM Composition. Co-author DOI 10.3390/cancers14153737↗
  11. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
  12. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s42003-021-02508-0↗
  13. The Cellular and Biological Impact of Extracellular Vesicles in Pancreatic Cancer. Last author DOI 10.3390/cancers13123040↗
  14. Correction: Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Co-author DOI 10.1038/s41419-020-2262-1↗
  15. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. Co-author DOI 10.15252/emmm.202012010↗
  16. Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling. Co-author DOI 10.1038/s41419-019-2116-x↗
  17. Stromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317570↗
  18. Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.411↗
  19. Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2018.1504727↗
  20. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. Last author DOI 10.1158/0008-5472.can-15-2790↗
  21. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. Last author DOI 10.1007/s00018-017-2579-9↗
  22. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Co-author DOI 10.1038/ncomms16031↗
  23. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/cdd.2016.18↗
  24. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Last author DOI 10.1172/jci87734↗
  25. Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. Last author DOI 10.1038/cddis.2014.557↗
  26. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1421601112↗
  27. IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation. Co-author DOI 10.1172/jci76037↗
  28. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1219555110↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sophie Vasseur · 13 shared papers, 2013–2026 · strength 1.36
  2. Jérémy Nigri · 14 shared papers, 2015–2023 · strength 1.26
  3. Fabienne Guillaumond · 12 shared papers, 2013–2026 · strength 1.19
  4. François Bertucci · 7 shared papers, 2021–2026 · strength 1.17
  5. Zainab Hussain · 5 shared papers, 2021–2026 · strength 1.03
  6. Nelson Dusetti · 9 shared papers, 2013–2026 · strength 0.96
  7. Juan Iovanna · 13 shared papers, 2013–2022 · strength 0.85
  8. Julie Leca · 7 shared papers, 2013–2022 · strength 0.48
  9. Corinne Bousquet · 6 shared papers, 2015–2023 · strength 0.48
  10. Moacyr Jesus Barreto de Melo Rêgo · 2 shared papers, 2024–2026 · strength 0.46
  11. Georgios Efthymiou · 2 shared papers, 2023–2025 · strength 0.35
  12. Cindy Neuzillet · 4 shared papers, 2019–2021 · strength 0.33
  13. Eric Mas · 2 shared papers, 2018–2026 · strength 0.31
  14. Olivier Soriani · 2 shared papers, 2022–2023 · strength 0.30
  15. Rémy Nicolle · 2 shared papers, 2021–2024 · strength 0.26
  16. Julie Roques · 5 shared papers, 2015–2018 · strength 0.26
  17. Christian Bressy · 5 shared papers, 2015–2018 · strength 0.25
  18. Rémi Samain · 3 shared papers, 2019–2021 · strength 0.25
  19. Rebecca Bennion · 1 shared paper, 2026 · strength 0.24
  20. Frédéric Bard · 1 shared paper, 2026 · strength 0.24
  21. Brice Chanez · 1 shared paper, 2026 · strength 0.24
  22. Martin James Humphries · 1 shared paper, 2026 · strength 0.24
  23. Jerome F. Cros · 3 shared papers, 2017–2021 · strength 0.23
  24. Valérie Hervieu · 3 shared papers, 2019–2020 · strength 0.23
  25. Jean‐Luc Van Laethem · 2 shared papers, 2017–2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.